CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of the Effect of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib on Disease Response in Patients With High Risk Smoldering Multiple Myeloma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02943473
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:54.208123+00:00
Published At: 2020-12-16T00:00:00+00:00
Record Updated At: 2020-12-16
Results Posted At: 2020-12-16
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["High Risk Smoldering Multiple Myeloma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-12-16"
protocolSection.identificationModule.nctId: "NCT02943473"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of the Effect of the Bruton\u0027s Tyrosine Kinase Inhibitor Ibrutinib on Disease Response in Patients With High Risk Smoldering Multiple Myeloma"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2020-12-16"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.